BUENA, N.J. , July 17, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced the hiring of Philip Yachmetz as Chief Legal Officer and Corporate Secretary of the Company, effective July 16,

BUENA, N.J. , June 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, announced today that it received notice from The NASDAQ Stock Market LLC (“NASDAQ”) on June 18, 2020 indicating that the Company

BUENA, N.J. , June 03, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, announced today conversion rate adjustments for the Company’s 7.0% Cash / 8.0% PIK Series B Senior Unsecured Convertible Notes

BUENA, N.J. , May 26, 2020 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, announced today that as of 12:01 a.m., Eastern Time , on May 28, 2020 it will effect a one-for-ten reverse stock split of its

BUENA, N.J. , May 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2020 . First Quarter 2020 Highlights Net Revenues for the first quarter of 2020

BUENA, N.J. , May 19, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Friday May 22 nd , 2020 to discuss the 1 st quarter 2020 financial results and business update.

BUENA, N.J. , April 08, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2019 . Fourth Quarter 2019 Highlights Net Revenues for the quarter

BUENA, N.J. , April 03, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00 a.m. ET on Wednesday, April 8, 2020 to discuss the 4 th quarter and 2019 full year financial results and

BUENA, N.J. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced a transition in leadership. Teligent has announced that Jason Grenfell-Gardner will be stepping down immediately

BUENA, N.J. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its development partner has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) for its abbreviated